(UroToday.com) The ASCO GU 2021 Genitourinary Cancers Symposium annual meeting included an invited discussion from Dr. Arlene Siefker-Radtke discussing “Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma” and “EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.”